412 related articles for article (PubMed ID: 19074748)
1. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study.
Goy A; Bernstein SH; Kahl BS; Djulbegovic B; Robertson MJ; de Vos S; Epner E; Krishnan A; Leonard JP; Lonial S; Nasta S; O'Connor OA; Shi H; Boral AL; Fisher RI
Ann Oncol; 2009 Mar; 20(3):520-5. PubMed ID: 19074748
[TBL] [Abstract][Full Text] [Related]
2. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.
Fisher RI; Bernstein SH; Kahl BS; Djulbegovic B; Robertson MJ; de Vos S; Epner E; Krishnan A; Leonard JP; Lonial S; Stadtmauer EA; O'Connor OA; Shi H; Boral AL; Goy A
J Clin Oncol; 2006 Oct; 24(30):4867-74. PubMed ID: 17001068
[TBL] [Abstract][Full Text] [Related]
3. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.
Goy A; Sinha R; Williams ME; Kalayoglu Besisik S; Drach J; Ramchandren R; Zhang L; Cicero S; Fu T; Witzig TE
J Clin Oncol; 2013 Oct; 31(29):3688-95. PubMed ID: 24002500
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma.
Baiocchi RA; Alinari L; Lustberg ME; Lin TS; Porcu P; Li X; Johnston JS; Byrd JC; Blum KA
Cancer; 2011 Jun; 117(11):2442-51. PubMed ID: 24048792
[TBL] [Abstract][Full Text] [Related]
5. Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study.
Wang M; Popplewell LL; Collins RH; Winter JN; Goy A; Kaminski MS; Bartlett NL; Johnston PB; Lister J; Fanning SR; Tuscano JM; Beck JT; Kaya H; Robeva A; Fan J; Klimovsky J; Cheung W; Cherfi A; O'Connor OA
Br J Haematol; 2014 May; 165(4):510-8. PubMed ID: 24579926
[TBL] [Abstract][Full Text] [Related]
6. Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial.
O'Connor OA; Moskowitz C; Portlock C; Hamlin P; Straus D; Dumitrescu O; Sarasohn D; Gonen M; Butos J; Neylon E; Hamelers R; Mac-Gregor Cortelli B; Blumel S; Zelenetz AD; Gordon L; Wright JJ; Vose J; Cooper B; Winter J
Br J Haematol; 2009 Apr; 145(1):34-9. PubMed ID: 19220284
[TBL] [Abstract][Full Text] [Related]
7. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma.
Friedberg JW; Vose JM; Kelly JL; Young F; Bernstein SH; Peterson D; Rich L; Blumel S; Proia NK; Liesveld J; Fisher RI; Armitage JO; Grant S; Leonard JP
Blood; 2011 Mar; 117(10):2807-12. PubMed ID: 21239695
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib for the treatment of mantle cell lymphoma.
Kane RC; Dagher R; Farrell A; Ko CW; Sridhara R; Justice R; Pazdur R
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5291-4. PubMed ID: 17875757
[TBL] [Abstract][Full Text] [Related]
9. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial.
Richardson PG; Barlogie B; Berenson J; Singhal S; Jagannath S; Irwin DH; Rajkumar SV; Srkalovic G; Alsina M; Anderson KC
Cancer; 2006 Mar; 106(6):1316-9. PubMed ID: 16470606
[TBL] [Abstract][Full Text] [Related]
10. Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma.
Di Bella N; Taetle R; Kolibaba K; Boyd T; Raju R; Barrera D; Cochran EW; Dien PY; Lyons R; Schlegel PJ; Vukelja SJ; Boston J; Boehm KA; Wang Y; Asmar L
Blood; 2010 Jan; 115(3):475-80. PubMed ID: 19965689
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
Goy A; Younes A; McLaughlin P; Pro B; Romaguera JE; Hagemeister F; Fayad L; Dang NH; Samaniego F; Wang M; Broglio K; Samuels B; Gilles F; Sarris AH; Hart S; Trehu E; Schenkein D; Cabanillas F; Rodriguez AM
J Clin Oncol; 2005 Feb; 23(4):667-75. PubMed ID: 15613697
[TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.
Leonard JP; Furman RR; Coleman M
Int J Cancer; 2006 Sep; 119(5):971-9. PubMed ID: 16557600
[TBL] [Abstract][Full Text] [Related]
13. Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial.
Goy A; Bernstein SH; McDonald A; Pickard MD; Shi H; Fleming MD; Bryant B; Trepicchio W; Fisher RI; Boral AL; Mulligan G
Leuk Lymphoma; 2010 Jul; 51(7):1269-77. PubMed ID: 20572799
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma.
Knopf KB; Duh MS; Lafeuille MH; Gravel J; Lefebvre P; Niculescu L; Ba-Mancini A; Ma E; Shi H; Comenzo RL
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):380-8. PubMed ID: 25023616
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
[TBL] [Abstract][Full Text] [Related]
16. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
Petrucci MT; Giraldo P; Corradini P; Teixeira A; Dimopoulos MA; Blau IW; Drach J; Angermund R; Allietta N; Broer E; Mitchell V; Bladé J
Br J Haematol; 2013 Mar; 160(5):649-59. PubMed ID: 23293914
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity.
Strauss SJ; Maharaj L; Hoare S; Johnson PW; Radford JA; Vinnecombe S; Millard L; Rohatiner A; Boral A; Trehu E; Schenkein D; Balkwill F; Joel SP; Lister TA
J Clin Oncol; 2006 May; 24(13):2105-12. PubMed ID: 16606971
[TBL] [Abstract][Full Text] [Related]
18. Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma.
Witzig TE; Luigi Zinzani P; Habermann TM; Tuscano JM; Drach J; Ramchandren R; Kalayoglu Besisik S; Takeshita K; Casadebaig Bravo ML; Zhang L; Fu T; Goy A
Am J Hematol; 2017 Oct; 92(10):E575-E583. PubMed ID: 28699256
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma.
Lamm W; Kaufmann H; Raderer M; Hoffmann M; Chott A; Zielinski C; Drach J
Haematologica; 2011 Jul; 96(7):1008-14. PubMed ID: 21486866
[TBL] [Abstract][Full Text] [Related]
20. Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG).
Conconi A; Martinelli G; Lopez-Guillermo A; Zinzani PL; Ferreri AJM; Rigacci L; Devizzi L; Vitolo U; Luminari S; Cavalli F; Zucca E
Ann Oncol; 2011 Mar; 22(3):689-695. PubMed ID: 20810546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
